Thymoquinone ameliorates diabetic phenotype in Diet-Induced Obesity mice via activation of SIRT-1-dependent pathways

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Karandrea, Shpetim ^a   Yin, Huquan ^a   Liang, Xiaomei ^a   Slitt, Angela L ^b   Heart, Emma A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NIGELLA SATIVA EXTRACT; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN 1; THYMOQUINONE; TRIACYLGLYCEROL; BENZOQUINONE DERIVATIVE; GLUCOSE BLOOD LEVEL; LIPID; SIRT1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLACK CUMIN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVATION; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION;

ANIMALS; BENZOQUINONES; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HEP G2 CELLS; HUMANS; INSULIN; LIPIDS; MALE; MICE; MICE, OBESE; OBESITY; PHOSPHORYLATION; SIRTUIN 1;

EID: 85029902945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0185374     Document Type: Article

References (54)

1. Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383: 1068–1083. https://doi.org/10.1016/S0140-6736(13)62154-6 PMID: 24315620
2. Bergman RN (2005) Minimal model: perspective from 2005. Horm Res 64: 8–15. https://doi.org/10.1159/000089312 PMID: 16439839
3. Fu Z, Gilbert ER, Liu D (2013) Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev 9: 25–53. PMID: 22974359
4. Ali BH, Blunden G (2003) Pharmacological and toxicological properties of Nigella sativa. Phytother Res 17: 299–305. https://doi.org/10.1002/ptr.1309 PMID: 12722128
5. Le PM, Benhaddou-Andaloussi A, Elimadi A, Settaf A, Cherrah Y, Haddad PS (2004) The petroleum ether extract of Nigella sativa exerts lipid-lowering and insulin-sensitizing actions in the rat. J Ethnophar-macol 94: 251–259. https://doi.org/10.1016/j.jep.2004.04.030 PMID: 15325727
6. Rchid H, Chevassus H, Nmila R, Guiral C, Petit P, Chokaïri M, et al. (2004) Nigella sativa seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. Fundam Clin Pharmacol 18: 525–529. https://doi.org/10.1111/j.1472-8206.2004.00275.x PMID: 15482373
7. Fararh KM, Shimizu Y, Shiina T, Nikami H, Ghanem MM, Takewaki T (2005) Thymoquinone reduces hepatic glucose production in diabetic hamsters. Res Vet Sci 79: 219–223. https://doi.org/10.1016/j.rvsc.2005.01.001 PMID: 16054891
8. Sankaranarayanan C, Pari L (2011) Thymoquinone ameliorates chemical induced oxidative stress and β-cell damage in experimental hyperglycemic rats. Chem Biol Interact 190: 148–154. https://doi.org/10.1016/j.cbi.2011.02.029 PMID: 21382363
9. Heart E, Palo M, Womack T, Smith PJ, Gray JP (2012) The level of menadione redox-cycling in pancreatic beta-cells is proportional to the glucose concentration: role of NADH and consequences for insulin secretion. Toxicol Appl Pharmacol 258: 216–25. https://doi.org/10.1016/j.taap.2011.11.002 PMID: 22115979
10. Gray JP, Karandrea S, Burgos DZ, Jaiswal AA, Heart EA (2016) NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells. Toxicol Lett 262: 1–11. https://doi.org/10.1016/j.toxlet.2016.08.021 PMID: 27558805
11. Gray JP, Burgos DZ, Yuan T, Seeram N, Rebar R, Follmer R, et al. (2016) Thymoquinone, a bioactive component of Nigella sativa, normalizes insulin secretion from pancreatic β-cells under glucose overload via regulation of malonyl-CoA. Am J Physiol Endocrinol Metab 310: E394–E404. https://doi.org/10.1152/ajpendo.00250.2015 PMID: 26786775
12. Berger F, Ramırez-Hernandez MH, Ziegler M (2004) The new life of a centenarian: signaling functions of NAD (P). Trends Biochem Sci 29: 111–118. https://doi.org/10.1016/j.tibs.2004.01.007 PMID: 15003268
13. Pollak N, Dölle C, Ziegler M (2007) The power to reduce: pyridine nucleotides—small molecules with a multitude of functions. Biochem J 402: 205–218. https://doi.org/10.1042/BJ20061638 PMID: 17295611
14. Wu J, Jin Z, Zheng H, Yan LJ (2016) Sources and implications of NADH/NAD+ redox imbalance in diabetes and its complications. Diabetes Metab Syndr Obes 9: 145–153. https://doi.org/10.2147/DMSO.S106087 PMID: 27274295
15. Kitada M, Koya D (2013) SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 37: 315–325. https://doi.org/10.4093/dmj.2013.37.5.315 PMID: 24199159
16. Pari L, Sankaranarayanan C (2009) Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin—nicotinamide induced diabetic rats. Life Sci 85: 830–834. https://doi.org/10.1016/j.lfs.2009.10.021 PMID: 19903489
17. Al-Ali A, Alkhawajah AA, Randhawa MA, Shaikh NA (2008) Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. J Ayub Med Coll Abbottabad, 20: 25–27. PMID: 19385451
18. Zhu D, Wang Y, Du Q, Liu Z, Liu X (2015) Cichoric acid reverses insulin resistance and suppresses inflammatory responses in the glucosamine-induced HepG2 cells. J Agric Food Chem 63: 10903–10913. https://doi.org/10.1021/acs.jafc.5b04533 PMID: 26592089
19. Zhu D, Zhang N, Zhou X, Zhang M, Liu Z, Liu X (2017) Cichoric acid regulates the hepatic glucose homeostasis via AMPK pathway and activates the antioxidant response in high glucose-induced hepa-tocyte injury. RSC Adv, 7: 1363–1375.
20. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W (1996) In: Applied linear statistical models, edited by Neter J. Chicago, IL: Irwin; 1992.
21. Wright SP (1992) Adjusted p-values for simultaneous inference. Biometrics 48: 1005–1013. https://doi.org/10.2307/2532694
22. Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ, Surwit RS (2004) Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53: 454–457. PMID: 15045691
23. Srinivasan K, Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125: 451–472. PMID: 17496368
24. Dula SB, Jecmenica M, Wu R, Jahanshahi P, Verrilli GM, Carter JD, et al. (2010) Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium 48: 133–142. https://doi.org/10.1016/j.ceca.2010.07.007 PMID: 20800281
25. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121: 2111–2117. https://doi.org/10.1172/JCI57132 PMID: 21633179
26. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. (2001) The hormone resistin links obesity to diabetes. Nature 409: 307–312. https://doi.org/10.1038/35053000 PMID: 11201732
27. Rodríguez IM, García JO, Sánchez JJA, González DA, Coello SD, Díaz BB, et al. (2016) Lipid and inflammatory biomarker profiles in early insulin resistance. Acta Diabetol 1–9. https://doi.org/10.1007/s00592-016-0885-6 PMID: 27432443
28. Santilli F, Liani R, Di Fulvio P, Formoso G, Simeone P, Tripaldi R, et al. (2016) Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thromb Haemost 116: 1089–1099. https://doi.org/10.1160/TH16-06-0471 PMID: 27709225
29. Tateya S, Tamori Y, Kawaguchi T, Kanda H, Kasuga M (2010) An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology 151: 971–979. https://doi.org/10.1210/en.2009-0926 PMID: 20056828
30. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S (2000) Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 121: 437–443. https://doi.org/10.1046/j.1365-2249.2000.01324.x PMID: 10971508
31. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, Garancini MP, et al. (2009) Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 32: 2105–2110. https://doi.org/10.2337/dc09-0763 PMID: 19641159
32. Zietz B, Büchler C, Herfarth H, Müller-Ladner U, Spiegel D, Schölmerich J, Schäffler A (2005) Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the–2518 A! G promoter polymorphism. Diabetes Obes Metab 7: 570–578. https://doi.org/10.1111/j.1463-1326.2004.00436.x PMID: 16050950
33. Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5: 150–159. https://doi.org/10.1038/ncpendmet1066 PMID: 19229235
34. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily conserved and non-conserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16: 4623–4635. https://doi.org/10.1091/mbc.E05-01-0033 PMID: 16079181
35. Muoio DM, Newgard CB (2008) Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9: 193–205. https://doi.org/10.1038/nrm2327
36. Tanti JF, Jager J (2009) Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 9: 753–762. https://doi.org/10.1016/j.coph.2009.07.004 PMID: 19683471
37. Dinkova-Kostova AT, Talalay P (2010) NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 501: 116–123. https://doi.org/10.1016/j.abb.2010.03.019 PMID: 20361926
38. Gaikwad A, Long DJ, Stringer JL, Jaiswal AK (2001) In vivo role of NAD(P)H: quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem 276: 22559–22564. https://doi.org/10.1074/jbc.M101053200 PMID: 11309386
39. Alkharfy KM, Ahmad A, Khan RM, Al-Shagha WM (2015) Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet 40: 319–323. https://doi.org/10.1007/s13318-014-0207-8 PMID: 24924310
40. Elmowafy M, Samy A, Raslan MA, Salama A, Said RA, Abdelaziz AE, El-Eraky W, El Awdan S, Viitala T (2016) Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostruc-tured lipid carrier (NLC) formulation. AAPS PharmSciTech, 17: 663–672. https://doi.org/10.1208/s12249-015-0391-0 PMID: 26304932
41. Ido Y (2007) Pyridine nucleotide redox abnormalities in diabetes. Antioxid Redox Signal 9: 931–942. https://doi.org/10.1089/ars.2007.1630 PMID: 17508915
42. Yan LJ (2014) Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res https://doi.org/10.1155/2014/137919 PMID: 25019091
43. Luo X, Li R, Yan LJ (2015) Roles of pyruvate, NADH, and mitochondrial complex I in redox balance and imbalance in β cell function and dysfunction. J Diabetes Res. https://doi.org/10.1155/2015/512618 PMID: 26568959
44. Khader M, Bresgen N, Eckl PM (2009) In vitro toxicological properties of thymoquinone. Food Chem Toxicol 47: 129–133. https://doi.org/10.1016/j.fct.2008.10.019 PMID: 19010375
45. Krauss RM, Siri PW (2004) Dyslipidemia in type 2 diabetes. Med Clin North Am 88: 897–909. https://doi.org/10.1016/j.mcna.2004.04.004 PMID: 15308384
46. Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46: 733–749. https://doi.org/10.1007/s00125-003-1111-y PMID: 12774165
47. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J. et al. (2005) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol 4: e31. https://doi.org/10.1371/journal.pbio.0040031 PMID: 16366736
48. Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, et al. (2007) SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 6: 307–319. https://doi.org/10.1016/j.cmet.2007.08.014 PMID: 17908559
49. Zhang J (2007) The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 282: 34356–34364. https://doi.org/10.1074/jbc.M706644200 PMID: 17901049
50. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al. (2010) AMPK and SIRT1: a longstanding partnership? Am J Physiol Endocrinol Metab 298: E751–E760. https://doi.org/10.1152/ajpendo.00745.2009 PMID: 20103737
51. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK (2014) AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 7: 241–253. https://doi.org/10.2147/DMSO.S43731 PMID: 25018645
52. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793–1801. https://doi.org/10.1172/JCI29069 PMID: 16823477
53. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, Bae EJ, et al. (2010) SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298: E419–E428. https://doi.org/10.1152/ajpendo.00417.2009 PMID: 19996381
54. Rashid S (2013) Mechanisms by which elevated resistin levels accelerate atherosclerotic cardiovascular disease. Rheumatol Curr Res 3: 115. https://doi.org/10.4172/2161-1149.1000115